米国の膵臓がん治療市場規模、シェア、動向分析レポート：タイプ別、治療法別、流通チャネル別、セグメント別予測、2025～2030年

米国の膵臓がん治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、米国の膵臓がん治療市場は2030年までに20億1,000万米ドルに達すると予測され、2025～2030年のCAGRは12.02％で成長すると予測されています。

この市場を牽引しているのは、膵臓がんの有病率の上昇、腫瘍学研究への資金提供の増加、新規治療のFDA承認などです。罹患率の上昇、高齢化、治療の進歩、強固な医療インフラが市場に影響を与える主要因です。

膵臓がんは最も侵攻性が高く致死的ながんのひとつであり、生存率の低さが特徴です。しかし、標的治療、免疫治療、外科手術における最近の動向は、この疾患を管理するための新たな時代を形成しつつあります。膵臓がんの治療オプションには、外科手術、化学治療、放射線治療、標的治療や免疫治療などの新たな治療が含まれます。外科的切除は依然として唯一の根治的選択肢であるが、末期診断のため10～20％の患者しか実行できないです。化学治療、特にFOLFIRINOXのようなゲムシタビンベースの併用治療が標準治療であり続けています。一方、KRASやBRCA1/2などの遺伝子変異に焦点を当てた標的治療や、チェックポイント阻害剤のような免疫治療アプローチが人気を集めています。

米国の膵臓がん治療市場で著名な企業には、Roche、Eli Lilly and Company、Bristol-Myers Squibb、AstraZeneca、Amgen Inc.などがあります。これらの企業は研究開発に積極的に投資しており、複数の新規治療を開発中です。進歩にもかかわらず、市場はいくつかの課題に直面しています。診断が遅れると多くの患者にとって治療の選択肢が狭まる一方、先進的な治療には高額な費用がかかります。さらに、信頼性の高いバイオマーカーがないことが、早期発見や個別化治療の開発を阻害し続けています。

今後、米国の膵臓がん治療市場は大きく前進する可能性があります。精密医療への取り組みにより、実用的な変異を特定することで、より個別化された治療が可能になります。早期発見と治療計画のための人工知能ベースのツールが普及しつつある一方、共同研究イニシアチブは薬剤開発と臨床検査を加速させています。官民パートナーシップもまた、膵臓がん治療におけるアンメットニーズへの対応において重要な役割を果たしています。

米国の膵臓がん治療市場は、変革的な成長の兆しを見せています。課題は残るもの、最先端技術と革新的な治療の統合は、患者の転帰改善に希望をもたらしています。製薬会社、研究者、医療プロバイダーを含む利害関係者は、この壊滅的な疾患に罹患した患者と家族の重要なニーズに対応するため、協力して取り組んでいます。次の10年間は、膵臓がん治療の展望を再構築し、この疾患のより良い管理に対する新たな希望と機会を提供することが約束されています。

米国の膵臓がん治療市場レポートハイライト

• タイプ別では、2024年の米国の膵臓がん治療市場において、外分泌セグメントが43.25%の最大売上シェアを占めました。この優位性は、症例の大半を占める外分泌性膵臓がんの有病率の高さ、このタイプを標的とした治療の進歩に起因します。
• 治療法別では、化学治療が43.25％のシェアで市場を独占し、予測期間中もリードを維持すると予想されます。化学治療、特にゲムシタビンベースのレジメンとFOLFIRINOXの広範な使用は、耐性や副作用などの課題にもかかわらず、膵臓がんの管理に役立っています。
• 流通チャネル別では、病院薬局が2024年に46.01%と最大の売上シェアを占め、今後も市場をリードしていくと予想されます。これは、膵臓がんの診断と治療のための入院患者数の増加と相まって、複雑な治療レジメンを管理する上で病院が果たす重要な役割によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の膵臓がん治療市場の変数、動向、範囲

• 親市場の展望
• 補助市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 膵臓がん治療分析ツール
  • ポーターの分析
  • PESTEL分析

第4章 米国の膵臓がん治療市場：タイプ別、推定・動向分析

• 米国の膵臓がん治療市場：タイプセグメントダッシュボード
• 米国の膵臓がん治療市場：タイプ変動分析、2024年と2030年
• 外分泌
• 内分泌

第5章 米国の膵臓がん治療市場：治療法別、推定・動向分析

• 米国の膵臓がん治療市場：治療セグメントダッシュボード
• 米国の膵臓がん治療市場：治療変動分析、2024年と2030年
• 化学治療
• 放射線治療
• その他

第6章 米国の膵臓がん治療市場：流通チャネル別、推定・動向分析

• 米国の膵臓がん治療市場：流通チャネルセグメントダッシュボード
• 米国の膵臓がん治療市場：流通チャネル変動分析、2024年と2030年
• 病院薬局
• 小売薬局
• その他

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業分類
• 企業ヒートマップ分析
• 企業プロファイル
  • Accuray Incorporated
  • AstraZeneca
  • Novartis AG
  • Pfizer Inc.
  • Genentech, Inc.（F. Hoffmann-La Roche Ltd）
  • Bristol-Myers Squibb Company
  • Ipsen Pharma
  • Eli Lilly and Company
  • Siemens Healthineers AG（Varian Medical Systems, Inc.）
  • Elekta AB

List of Tables

• Table 1 List of abbreviation
• Table 2 U.S. Pancreatic Cancer Treatment Market, by country, 2018 - 2030 (USD Million)
• Table 3 U.S. Pancreatic Cancer Treatment Market, by Type, 2018 - 2030 (USD Million)
• Table 4 U.S. Pancreatic Cancer Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 5 U.S. Pancreatic Cancer Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 U.S. Pancreatic Cancer Treatment Market Segmentation
• Fig. 8 Market Snapshot, 2024
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 U.S. Pancreatic Cancer Treatment Market: Type movement analysis
• Fig. 16 U.S. Pancreatic Cancer Treatment Market: Type outlook and key takeaways
• Fig. 17 U.S. Exocrine pancreatic cancer treatment market estimates and forecasts, 2018 - 2030
• Fig. 18 U.S. Endocrine pancreatic cancer treatment market estimates and forecasts, 2018 - 2030
• Fig. 19 U.S. Pancreatic cancer treatment market: Treatment movement analysis
• Fig. 20 U.S. Pancreatic cancer treatment market: Treatment outlook and key takeaways
• Fig. 21 U.S. Chemotherapy market estimates and forecasts, 2018 - 2030
• Fig. 22 U.S. Radiation Therapy market estimates and forecasts, 2018 - 2030
• Fig. 23 U.S. Others market estimates and forecasts, 2018 - 2030
• Fig. 24 U.S. Pancreatic cancer treatment market: Distribution Channel movement analysis
• Fig. 25 U.S. Pancreatic cancer treatment market: Distribution Channel outlook and key takeaways
• Fig. 26 U.S. Hospital Pharmacies market estimates and forecasts, 2018 - 2030
• Fig. 27 U.S. Retail Pharmacies market estimates and forecasts, 2018 - 2030
• Fig. 28 U.S. Others market estimates and forecasts, 2018 - 2030

U.S. Pancreatic Cancer Treatment Market Growth & Trends:

The U.S. pancreatic cancer treatment market is anticipated to reach USD 2.01 billion by 2030 and is expected to grow at a CAGR of 12.02% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising prevalence of pancreatic cancer, increased funding for oncology research, and FDA approvals for novel therapies. Rising incidence rates, an aging population, therapeutic advances, and robust healthcare infrastructure are key factors influencing the market.

Pancreatic cancer is one of the most aggressive and lethal forms of cancer, characterized by poor survival rates. However, recent developments in targeted therapies, immunotherapies, and surgical procedures are shaping a new era for managing the disease.Treatment options for pancreatic cancer include surgery, chemotherapy, radiation therapy, and emerging therapies such as targeted therapy and immunotherapy. Surgical resection remains the only potential curative option but is viable for only 10-20% of patients due to late-stage diagnosis. Chemotherapy, particularly gemcitabine-based combinations like FOLFIRINOX, continues to be the standard treatment. Meanwhile, targeted therapies focusing on genetic mutations such as KRAS and BRCA1/2 and immunotherapy approaches like checkpoint inhibitors are gaining traction.

Prominent U.S. pancreatic cancer treatment market players include Roche, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca, and Amgen Inc. These companies are actively investing in research and development, with several novel therapies in the pipeline.Despite advancements, the market faces several challenges. Late diagnosis limits treatment options for many patients, while the high costs of advanced therapies can be prohibitive. Additionally, the lack of reliable biomarkers continues to hamper early detection and the development of personalized treatments.

Looking forward, the U.S. pancreatic cancer treatment market is poised for significant advancements. Efforts in precision medicine enable more personalized treatments by identifying actionable mutations. Artificial intelligence-based tools for early detection and treatment planning are gaining traction, while collaborative research initiatives are accelerating drug development and clinical trials. Public-private partnerships are also playing a crucial role in addressing unmet needs in pancreatic cancer treatment.

The U.S. pancreatic cancer treatment market is on the cusp of transformative growth. While challenges persist, the integration of cutting-edge technologies and innovative therapies offers hope for improved patient outcomes. Stakeholders, including pharmaceutical companies, researchers, and healthcare providers, are working collaboratively to address the critical needs of patients and families affected by this devastating disease. The next decade promises to reshape the landscape of pancreatic cancer treatment, offering new hope and opportunities for better management of this condition.

U.S. Pancreatic Cancer Treatment Market Report Highlights:

• On the basis of type, the exocrine segment held the largest revenue share of 43.25% of the U.S. pancreatic cancer treatment market in 2024. This dominance is attributed to the high prevalence of exocrine pancreatic cancer, which accounts for the majority of cases, and advancements in treatment modalities targeting this type.
• Based on treatment, the chemotherapy dominated the market with a share of 43.25% and is expected to maintain its lead during the forecast period. The widespread use of chemotherapy, particularly gemcitabine-based regimens and FOLFIRINOX, has been instrumental in managing pancreatic cancer, despite challenges such as resistance and side effects.
• Based on distribution channel, the hospital pharmacies accounted for the largest revenue share of 46.01% in 2024 and are expected to continue leading the market. This is due to the critical role hospitals play in administering complex treatment regimens, coupled with the increasing number of inpatient visits for pancreatic cancer diagnosis and treatment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Pancreatic Cancer Treatment Market Variables, Trends, & Scope

• 3.1. Parent Market Outlook
• 3.2. Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Rising Prevalence of Pancreatic Cancer
    • 3.3.1.2. Advancements in Modern Therapeutics
    • 3.3.1.3. Growing Investments in Pancreatic Cancer R&D
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. High Cost of Advanced Therapies
    • 3.3.2.2. Stringent Regulatory and Reimbursement Challenges
• 3.4. Pancreatic Cancer Treatment Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. Pancreatic Cancer Treatment Market: By Type Estimates & Trend Analysis

• 4.1. U.S. Pancreatic Cancer Treatment Market: Type Segment Dashboard
• 4.2. U.S. Pancreatic Cancer Treatment Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Exocrine
  • 4.3.1. Exocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Endocrine
  • 4.4.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Pancreatic Cancer Treatment Market: Treatment Estimates & Trend Analysis

• 5.1. U.S. Pancreatic Cancer Treatment Market: Treatment Segment Dashboard
• 5.2. U.S. Pancreatic Cancer Treatment Market: By Treatment Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Chemotherapy
  • 5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Radiation Therapy
  • 5.4.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Estimates & Trend Analysis

• 6.1. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Segment Dashboard
• 6.2. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Hospital Pharmacies
  • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Retail Pharmacies
  • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Heat Map Analysis
• 7.4. Company Profiles
  • 7.4.1. Accuray Incorporated
    • 7.4.1.1. Participant's Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Recent Developments/ Strategic Initiatives
  • 7.4.2. AstraZeneca
    • 7.4.2.1. Participant's Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Recent Developments/ Strategic Initiatives
  • 7.4.3. Novartis AG
    • 7.4.3.1. Participant's Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Recent Developments/ Strategic Initiatives
  • 7.4.4. Pfizer Inc.
    • 7.4.4.1. Participant's Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Recent Developments/ Strategic Initiatives
  • 7.4.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • 7.4.5.1. Participant's Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Recent Developments/ Strategic Initiatives
  • 7.4.6. Bristol-Myers Squibb Company
    • 7.4.6.1. Participant's Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Recent Developments/ Strategic Initiatives
  • 7.4.7. Ipsen Pharma
    • 7.4.7.1. Participant's Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Recent Developments/ Strategic Initiatives
  • 7.4.8. Eli Lilly and Company
    • 7.4.8.1. Participant's Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Recent Developments/ Strategic Initiatives
  • 7.4.9. Siemens Healthineers AG (Varian Medical Systems, Inc., part of the company)
    • 7.4.9.1. Participant's Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Recent Developments/ Strategic Initiatives
  • 7.4.10. Elekta AB
    • 7.4.10.1. Participant's Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Recent Developments/ Strategic Initiatives